{"doi":"10.1016/j.annonc.2020.04.059","title":"O-6 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma","abstract":null,"journal":"Annals of Oncology","year":2020,"id":625640,"datarank":0.37273599746820013,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"self_citation_contribution":0.37273599746820013,"citation_network_contribution":0.0,"self_endowment_contribution":0.37273599746820013,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1572684,"name":"M. Kudo","orcid":null,"position":1,"is_corresponding":false},{"id":1009204,"name":"W. Harris","orcid":null,"position":2,"is_corresponding":false},{"id":1543675,"name":"M. Ikeda","orcid":null,"position":3,"is_corresponding":false},{"id":1618146,"name":"T. Okusaka","orcid":null,"position":4,"is_corresponding":false},{"id":1618147,"name":"Y. Kang","orcid":null,"position":5,"is_corresponding":false},{"id":1618148,"name":"S. Qin","orcid":null,"position":6,"is_corresponding":false},{"id":1618149,"name":"D. Tai","orcid":null,"position":7,"is_corresponding":false},{"id":41381,"name":"H. Lim","orcid":"0009-0008-4945-1423","position":8,"is_corresponding":false},{"id":1618150,"name":"T. Yau","orcid":null,"position":9,"is_corresponding":false},{"id":1618151,"name":"W. Yong","orcid":null,"position":10,"is_corresponding":false},{"id":1598501,"name":"A. Cheng","orcid":null,"position":11,"is_corresponding":false},{"id":1614787,"name":"A. Gasbarrini","orcid":null,"position":12,"is_corresponding":false},{"id":1618152,"name":"F. de Braud","orcid":null,"position":13,"is_corresponding":false},{"id":1618153,"name":"J. Bruix","orcid":null,"position":14,"is_corresponding":false},{"id":1618154,"name":"M. Borad","orcid":null,"position":15,"is_corresponding":false},{"id":1618155,"name":"N. Standifer","orcid":null,"position":16,"is_corresponding":false},{"id":1618156,"name":"P. He","orcid":null,"position":17,"is_corresponding":false},{"id":1572717,"name":"A. Negro","orcid":null,"position":18,"is_corresponding":false},{"id":1618157,"name":"G. Vlahovic","orcid":null,"position":19,"is_corresponding":false},{"id":1572679,"name":"B. Sangro","orcid":null,"position":20,"is_corresponding":false},{"id":1618158,"name":"G. Abou-Alfa","orcid":null,"position":21,"is_corresponding":false},{"id":47311,"name":"R. Kelley","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"O-6 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma","abstract":null,"is_dataset_classified":null,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19767382","pmcid":null,"openalex_id":"https://openalex.org/W3041684384","authors":[],"funders":[],"total_grants":0,"fwci":0.8355,"citation_percentile":0.74502862,"influential_citations":0,"citation_trend":[{"year":2020,"count":1},{"year":2021,"count":7},{"year":2022,"count":2},{"year":2023,"count":1}],"oa_status":"bronze","license":"http://www.elsevier.com/open-access/userlicense/1.0/","oa_locations":[{"url":"http://www.annalsofoncology.org/article/S0923753420393583/pdf","host_type":"journal"},{"url":"http://www.annalsofoncology.org/article/S0923753420393583/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0923753420393583?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0923753420393583?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.annonc.2020.04.059","host_type":"journal"}],"fields_of_study":["Cancer Immunotherapy and Biomarkers","Ferroptosis and cancer prognosis","Hepatocellular Carcinoma Treatment and Prognosis"],"mesh_terms":[],"keywords":["Tremelimumab","Durvalumab","Medicine","Regimen","Tolerability","Oncology","Adverse effect","Internal medicine","Immunotherapy","Cancer","Nivolumab","Ipilimumab"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T07:21:22.557464Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}